Piston Bio

Building an Extended Half-Life Oncology Company

September 21, 2026

Walter Hong, MD
Chief Executive Officer
walterhong@pistonbio.com

Piston Bio Pipeline

Program	Mechanism	Target indication	Ownership	IP	Stage
PST-102	Extended half-life TLR7/8 agonist	Second-line or later non-small cell lung cancer (2L+ NSCLC)	100% owned	Composition of matter	IND-enabling
PST-101	Extended half-life A2A antagonist	Cancer-related apathy	100% owned	Composition of matter	FDA-aligned Phase 2

PST-102: Extended Half-Life TLR7/8 Agonist

Designed for sustained TLR7/8 engagement throughout the Q3W dosing interval

1 Resiquimod

Clinically validated
TLR7/8 agonist



- **Established systemic safety and PK/PD experience**
- **~64% ORR in Phase 2 1L NSCLC combination study**
  EIK1001 + pembrolizumab + chemotherapy (TeLuRide-005). Patients with stage IV NSCLC.

2 PST-102

Proprietary molecular modification

DESIGNED TO EXTEND EXPOSURE

while preserving
TLR7/8 pharmacologic activity

- Maintained TLR7/8 potency and activity
- Favorable PK profile

3 Extended Exposure

Designed for sustained
target engagement



- Continuous innate and adaptive immune priming
- Designed for durable exposure

Takeaway: PST-102 is engineered for durable target engagement—helping avoid troughs in exposure.

PST-102: Billion-Dollar Opportunity in 2L+ NSCLC

TAM $20-30B+

Global NSCLC therapeutics market

SAM $3-6B

~150K-220K 2L+ NSCLC patients annually (US + EU)

Post–PD-1 where standard; inclusive of global PD-1–naïve patients

SOM $1B+ peak potential

20-30% share of 2L+ NSCLC

Add-on to docetaxel in 2L+ NSCLC

PST-101: FDA Alignment Establishes Phase 2 Path

- Type B Pre-IND meeting completed with FDA
- FDA alignment established key elements of the proposed Phase 2 clinical development strategy for the parent A2A receptor antagonist program in cancer-related apathy.
  - Randomized, placebo-controlled study
  - NSCLC
  - Primary endpoint: AES-C
- PST-101 has since evolved into a proprietary next-generation A2A receptor antagonist protected by composition-of-matter intellectual property.
- The FDA-aligned clinical development strategy provides a strong regulatory foundation for advancing next-generation PST-101

Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Research. 1991;38:143–162.

Intellectual Property Strategy

A repeatable strategy for building differentiated, composition-of-matter–protected therapeutics.

Piston Bio

1 **VALIDATED SCAFFOLD**

Targets with strong biology and clinical rationale

→

2 **TARGETED MOLECULAR MODIFICATION**

Selective modification designed to extend half-life while preserving pharmacologic activity

→

3 **COMPOSITION-OF-MATTER IP**

Broad and robust IP protection for differentiated small molecules

→

4 **PIPELINE**

PST-102 – TLR7/8 agonist

PST-101 – A2A antagonist

Future programs

(cytokines and other targets)

Long-Term Pipeline Expansion and Value Creation

Multiple opportunities for development and partnership

World-Class Leadership & Advisors

Walter Hong, MD
Founder and CEO, Piston Bio

Antoni Ribas, MD, PhD
UCLA – Tumor Immunology

Adil Daud, MD
UCSF – Melanoma Clinical Research

Matthew Zibelman, MD
Fox Chase Cancer Center – Genitourinary Research

Why Piston Bio

- Proprietary small-molecule platform with composition-of-matter intellectual property
- Differentiated lead oncology program (PST-102) targeting systemic TLR7/8 activation
- FDA-aligned, Phase 2-ready supportive oncology program (PST-101)
- Multiple programs with near-term development opportunities